Objective and noninvasive biochemical markers in rheumatoid arthritis: where are we and where are we going?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Objective and noninvasive biochemical markers in rheumatoid arthritis : where are we and where are we going? / Bay-Jensen, Anne C.; Siebuhr, Anne Sofie; Damgaard, Dres; Drobinski, Patryk; Thudium, Christian; Mortensen, Joachim; Nielsen, Claus H.
I: Expert Review of Proteomics, Bind 18, Nr. 3, 2021, s. 159-175.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Objective and noninvasive biochemical markers in rheumatoid arthritis
T2 - where are we and where are we going?
AU - Bay-Jensen, Anne C.
AU - Siebuhr, Anne Sofie
AU - Damgaard, Dres
AU - Drobinski, Patryk
AU - Thudium, Christian
AU - Mortensen, Joachim
AU - Nielsen, Claus H.
N1 - Publisher Copyright: © 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 1% of the adult population. RA is multi-factorial, and as such our understanding of the molecular pathways involved in the disease is currently limited. An increasing number of studies have suggested that several molecular phenotypes (i.e. endotypes) of RA exist, and that different endotypes respond differently to various treatments. Biochemical markers may be an attractive means for achieving precision medicine, as they are objective and easily obtainable. Areas covered: We searched recent publications on biochemical markers in RA as either diagnostic or prognostic markers, or as markers of disease activity. Here, we provide a narrative overview of different classes of markers, such as autoantibodies, citrulline products, markers of tissue turnover and cytokines, that have been tested in clinical cohorts or trials including RA patients. Expert opinion: Although many biochemical markers have been identified and tested, few are currently being used in clinical practice. As more treatment options are becoming available, the need for precision medicine tools that can aid physicians and patients in choosing the right treatment is growing.
AB - Introduction: Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 1% of the adult population. RA is multi-factorial, and as such our understanding of the molecular pathways involved in the disease is currently limited. An increasing number of studies have suggested that several molecular phenotypes (i.e. endotypes) of RA exist, and that different endotypes respond differently to various treatments. Biochemical markers may be an attractive means for achieving precision medicine, as they are objective and easily obtainable. Areas covered: We searched recent publications on biochemical markers in RA as either diagnostic or prognostic markers, or as markers of disease activity. Here, we provide a narrative overview of different classes of markers, such as autoantibodies, citrulline products, markers of tissue turnover and cytokines, that have been tested in clinical cohorts or trials including RA patients. Expert opinion: Although many biochemical markers have been identified and tested, few are currently being used in clinical practice. As more treatment options are becoming available, the need for precision medicine tools that can aid physicians and patients in choosing the right treatment is growing.
KW - biochemical markers
KW - endotypes
KW - precision medicine
KW - Rheumatoid arthritis
U2 - 10.1080/14789450.2021.1908892
DO - 10.1080/14789450.2021.1908892
M3 - Review
C2 - 33783300
AN - SCOPUS:85105847214
VL - 18
SP - 159
EP - 175
JO - Expert Review of Proteomics
JF - Expert Review of Proteomics
SN - 1478-9450
IS - 3
ER -
ID: 307007787